Antibe Therapeutics (Antibe Therapeutics) 5-Year ROIIC % : -63.69% (As of Mar. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Antibe Therapeutics 5-Year ROIIC %?

5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year. Antibe Therapeutics's 5-Year ROIIC % for the quarter that ended in Mar. 2023 was -63.69%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Antibe Therapeutics's 5-Year ROIIC % or its related term are showing as below:

ATBPF's 5-Year ROIIC % is ranked worse than
62.54% of 1380 companies
in the Biotechnology industry
Industry Median: -19.115 vs ATBPF: -63.69

Antibe Therapeutics 5-Year ROIIC % Historical Data

The historical data trend for Antibe Therapeutics's 5-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antibe Therapeutics 5-Year ROIIC % Chart

Antibe Therapeutics Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

5-Year ROIIC %

Get a 7-Day Free Trial

-170.14

-282.50

1,200.94

-84.79

-63.69

Antibe Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
5-Year ROIIC %	Get a 7-Day Free Trial															-	-63.69	-	-	-

Competitive Comparison of Antibe Therapeutics's 5-Year ROIIC %

For the Biotechnology subindustry, Antibe Therapeutics's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Antibe Therapeutics's 5-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Antibe Therapeutics's 5-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Antibe Therapeutics's 5-Year ROIIC % falls into.

Antibe Therapeutics 5-Year ROIIC % Calculation

Antibe Therapeutics's 5-Year ROIIC % for the quarter that ended in Mar. 2023 is calculated as:

5-Year ROIIC %	=	5-Year Incremental Net Operating Profit After Taxes (NOPAT)^**	/	5-Year Incremental Invested Capital^**
	=	( -15.016 (Mar. 2023) - -4.9685226 (Mar. 2018) )	/	( 21.205 (Mar. 2023) - 5.293 (Mar. 2018) )
	=	-10.0474774	/	15.912
	=	-63.14%^***

** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.

Antibe Therapeutics (OTCPK:ATBPF) 5-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.

Antibe Therapeutics 5-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Antibe Therapeutics's 5-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.

Antibe Therapeutics (Antibe Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antibe Therapeutics Inc (OTCPK:ATBPF) » Definitions » 5-Year ROIIC %

Comparable Companies

Traded in Other Exchanges

ATE:Canada

Address

15 Prince Arthur Avenue, Toronto, ON, CAN, M5R 1B2

Website

https://www.antibethera.com

Antibe Therapeutics Inc is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The company's pipeline includes assets that seek to overcome gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs. Antibe's lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids for post-operative pain. Antibe's second pipeline drug, ATB-352, is being developed for a specialized acute pain indication. The company's anticipated next target is inflammatory bowel disease, a condition long in need of safer, more effective therapies.